The CDC Advisory Committee on Immunization Practices (ACIP) recommends that Novavax’s COVID-19 vaccine is to be used as another primary series option for adults ages 18 years and older. Novavax’s COVID-19 vaccine, which will be available in the coming weeks, is an important tool in the pandemic.
The Novavax provides a more familiar type of COVID-19 vaccine technology for adults and having multiple types of vaccines offers more options and flexibility for the public, jurisdictions and vaccine providers.
Attend the CDC COCA Call on July 28 to learn more. Details below.
CDC COCA Call: Recommendations for the Novavax COVID-19 Primary Series in Adults Ages 18 and Older
July 28, 2022 | 1:00 pm CT.
COVID-19 vaccination provides protection against serious illness and outcomes associated with COVID-19, including emergency department or urgent care visits, hospitalizations, and death. The Novavax COVID-19 vaccine is the first COVID-19 protein subunit vaccine recommended for use in the United States that is built on a familiar type of vaccine technology. Other protein subunit vaccines have been used for more than 30 years in the United States, including for hepatitis B, HPV, and acellular pertussis (whooping cough) vaccines. During this COCA Call, presenters will discuss CDC’s new guidance on the Novavax COVID-19 vaccine for adults ages 18 years and older, including adults who are moderately or severely immunocompromised.
Register to attend the August 16 Immunizations Roundtable, hosted by Great Plains QIN, as we will address the Novavax vaccine during the discussion. Register here.